SAN FRANCISCO, Jan. 9, 2020 – LACHESIS BIOSCIENCES LTD, a clinical-stage biotechnology company targeting dementia caused by Alzheimer’s and Parkinson’s disease, announced today that its chief executive officer, Dr. Tim Morgan, will present at the Biotech Showcase 2020 conference being held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco, California.
General presentation information: Lachesis is developing a patented rivastigmine nasal spray candidate that’s low-risk, with high-return potential. Our presentation includes positive clinical and usability data, future-plans and emphasizes why you should trust us to advance dementia treatment. We make it easier for patients to take higher doses of this important dementia medication.
About LACHESIS BIOSCIENCES
A clinical-stage biotechnology company using its patented, nasal drug delivery technology to advance treatments for dementia and agitation associated with Alzheimer’s and Parkinson’s disease.
